If you or a loved one is on Tysabri, you may wonder what ongoing monitoring involves to watch for PML. Decades of pharmacovigilance have established a structured clinical workup that includes regular MRI scans and lab tests. This page explains the standard monitoring protocol and what each step means for your care.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Ohio who have developed PML after Tysabri treatment, understanding the medical evidence, risk factors, and legal considerations—including the statute of limitations—is essential. The prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical data and postmarketing reports. PML is caused by reactivation of the JC virus in immunocompromised individuals, and Tysabri's mechanism of action—blocking lymphocyte migration into the central nervous system—is believed to impair immune surveillance, allowing the virus to proliferate in the brain.
Three primary risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML. The label advises that these factors "should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation of PML typically includes progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis is confirmed through brain MRI and detection of JC virus DNA in cerebrospinal fluid. The prognosis is poor, with most cases leading to severe disability or death. The timeline between Tysabri exposure and documented harm can vary; PML may develop after months to years of treatment, and symptoms can emerge even after discontinuation of the drug.
From a risk perspective, the adequacy of warnings regarding Tysabri and PML is a central issue. The boxed warning and the TOUCH Prescribing Program are designed to inform patients and prescribers of the risks. However, questions may arise about whether these warnings were sufficient to allow patients to make fully informed decisions, particularly given the severity of PML. For affected patients in Ohio, settlement-related considerations may include the need to demonstrate that the drug's risks were not adequately communicated or that monitoring was insufficient. The statute of limitations for filing a Tysabri-related PML lawsuit in Ohio is generally governed by the state's product liability laws. In Ohio, the statute of limitations for personal injury claims is typically two years from the date the injury was discovered or should have been discovered. For PML, this date may be when the patient first experienced symptoms or received a diagnosis. Given the latency period between Tysabri exposure and PML onset, careful documentation of the timeline is critical. Patients should consult with a legal professional to determine how the statute applies to their specific circumstances. In summary, Tysabri carries a known risk of PML, with identifiable risk factors including anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use. The drug's labeling includes a boxed warning and monitoring requirements. For Ohio patients who have developed PML, the statute of limitations for legal action is typically two years from discovery of the injury. Settlement considerations may involve evaluating the adequacy of warnings and the timeline between exposure and harm.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Ohio, the statute of limitations for personal injury claims, including those related to Tysabri and PML, is generally two years from the date the injury was discovered or should have been discovered. For PML, this date may be when the patient first experienced symptoms or received a diagnosis. Given the latency period between Tysabri exposure and PML onset, careful documentation of the timeline is critical. Patients should consult with a legal professional to determine how the statute applies to their specific circumstances.
Three primary risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML. The label advises that these factors should be considered when initiating and continuing treatment with Tysabri.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.